Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
247 hedge funds and large institutions have $4.73B invested in Global Blood Therapeutics, Inc. in 2022 Q3 according to their latest regulatory filings, with 114 funds opening new positions, 54 increasing their positions, 58 reducing their positions, and 61 closing their positions.
117% more capital invested
Capital invested by funds: $2.18B → $4.73B (+$2.55B)
110% more funds holding in top 10
Funds holding in top 10: 10 → 21 (+11)
87% more first-time investments, than exits
New positions opened: 114 | Existing positions closed: 61
68% more call options, than puts
Call options by funds: $145M | Put options by funds: $86.1M
27% more funds holding
Funds holding: 195 → 247 (+52)
7% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$176M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$125M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$123M |
| 4 |
JP Morgan Chase
New York
|
+$105M |
| 5 |
GCL
Glazer Capital LLC
New York
|
+$77.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$183M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$144M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$140M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$126M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$114M |
GBT Hedge Fund Activity: Q3 2022 in Review
247 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2022, worth a combined $4.73B — up 117% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 114 funds opened new GBT positions and 61 closed out — a net gain of 53 holders — while 54 added to existing stakes and 58 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $176M. The largest seller was Deep Track Capital, cutting an estimated $183M.
- 247 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2022, up from 195 in Q2 2022.
- Funds reported $4.73B of Global Blood Therapeutics, Inc. stock for Q3 2022, up 117% quarter-over-quarter.
- 114 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2022 and 61 closed out, a net change of +53 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q3 2022 was Pentwater Capital Management, an estimated $176M added.
- The largest Global Blood Therapeutics, Inc. seller in Q3 2022 was Deep Track Capital, an estimated $183M sold.
Based on aggregated 13F filings for Q3 2022.